ライフサイエンスコーパス: systemic sclerosis

1 , including systemic lupus erythematosus and systemic sclerosis.

2 he diagnosis and management of patients with systemic sclerosis.

3 ures, whose pathogenesis may be similar with systemic sclerosis.

4 tions in five large cohorts of patients with systemic sclerosis.

5 CXCL4 predicted the risk and progression of systemic sclerosis.

6 d with four independent data sets focused on systemic sclerosis.

7 cells and skin transcriptome changes, as in systemic sclerosis.

8 een in patients with the autoimmune disease, systemic sclerosis.

9 n 156 patients with severe diffuse cutaneous systemic sclerosis.

10 link between epidermal c-Rel expression and systemic sclerosis.

11 e asthma, idiopathic pulmonary fibrosis, and systemic sclerosis.

12 is and of other fibrotic disorders including systemic sclerosis.

13 in progressive vasculopathy in patients with systemic sclerosis.

14 tedanib in patients with ILD associated with systemic sclerosis.

15 atment of pulmonary arterial hypertension in systemic sclerosis.

16 pecimens of skin and lung from patients with systemic sclerosis.

17 lung injury, including that associated with systemic sclerosis.

18 of morbidity and mortality in patients with systemic sclerosis.

19 s as potential therapeutic interventions for systemic sclerosis.

20 the vascular manifestations associated with systemic sclerosis.

21 upus erythematosus, rheumatoid arthritis and systemic sclerosis.

22 leading cause of mortality in patients with systemic sclerosis.

23 general population and >90% of patients with systemic sclerosis.

24 ease and severe skin disease associated with systemic sclerosis.

25 ase-modifying therapies for the treatment of systemic sclerosis.

26 s a concern in an autoimmune disease such as systemic sclerosis.

27 therapies promise to have a major impact in systemic sclerosis.

28 on on platelet contributions, in general, to systemic sclerosis.

29 nib was observed for other manifestations of systemic sclerosis.

30 ome of autoimmune rheumatic diseases such as systemic sclerosis.

31 ethylome in primary T cells of patients with systemic sclerosis.

32 l class of genes involved in pathogenesis of systemic sclerosis.

33 released in a higher amount in patients with systemic sclerosis.

34 the sera of patients with diffuse cutaneous systemic sclerosis.

35 atibility complex haplotypes associated with systemic sclerosis.

36 d with immune-mediated conditions, including systemic sclerosis.

37 sociation (P = 8.5 x 10(-22); OR = 4.3) with systemic sclerosis.

38 f interstitial lung disease in patients with systemic sclerosis.

39 diseases of systemic lupus erythematosus and systemic sclerosis.

40 he faSScinate phase 2 trial in patients with systemic sclerosis.

41 rticipants, the nailfolds in 2 patients with systemic sclerosis, 1 patient with dermatomyositis, and

42 ) has been implicated in driving fibrosis in systemic sclerosis, a mechanism-derived gene expression

43 osus affects from 161,000 to 322,000 adults, systemic sclerosis affects 49,000 adults, and primary Sj

44 Endothelin-1 promotes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blo

45 Systemic sclerosis, also called scleroderma, is an immun

46 st potential efficacy of imatinib in diffuse systemic sclerosis, although adverse events are common.

47 ical and histopathological similarities with systemic sclerosis, an autoimmune disease whose risk is

48 In the discovery stage, 527 patients with systemic sclerosis and 5,024 controls were recruited and

49 g disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic scler

50 Participants were patients with systemic sclerosis and active digital ulcers at baseline

51 Among patients with systemic sclerosis and active ischemic digital ulcers, t

52 entially regulated between diffuse cutaneous systemic sclerosis and controls and correlated with modi

53 vels of CXCL4 were elevated in patients with systemic sclerosis and correlated with the presence and

54 microcirculation plays an important role in systemic sclerosis and dermatomyositis.

55 Here, we review the clinical features of systemic sclerosis and describe the best practice approa

56 proteome of patients with diffuse cutaneous systemic sclerosis and identified differentially express

57 ling and participates in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis.

58 nflammatory effects in preclinical models of systemic sclerosis and ILD.

59 s aberrantly expressed in lesional tissue in systemic sclerosis and in a murine model of scleroderma.

60 s with diffuse systemic sclerosis or limited systemic sclerosis and interstitial lung disease who wer

61 the prototypic fibrotic autoimmune condition systemic sclerosis and is known to induce collagen I exp

62 the traditional skin score in patients with systemic sclerosis and may additionally aid in the monit

63 pathway may represent a novel treatment for systemic sclerosis and other fibrotic diseases.

64 allmark of many fibrotic diseases, including systemic sclerosis and pulmonary, liver, and kidney fibr

65 characterized autoimmune diseases, including systemic sclerosis and Sjogren syndrome.

66 sma levels of CXCL4 protein with features of systemic sclerosis and studied the direct effects of CXC

67 eir receptor has been noted in patients with systemic sclerosis and systemic lupus erythematosus with

68 phenotype are also elevated in patients with systemic sclerosis and systemic lupus erythematosus, sug

69 tic studies on stem cell transplantation for systemic sclerosis and their implications for clinical p

70 in a sample of human patients diagnosed with systemic sclerosis and to an experiment that examined mu

71 complications are important in scleroderma (systemic sclerosis) and include scleroderma renal crisis

72 anib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenola

73 c lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutrophil cytoplasmic anti

74 rs as chronic obstructive pulmonary disease, systemic sclerosis, and kidney diseases.

75 eases, such as systemic lupus erythematosus, systemic sclerosis, and myositis.

76 Genetic components associated with systemic sclerosis are also associated with sclerotic GV

77 Digital ulcers in patients with systemic sclerosis are associated with pain and poor qua

78 chronically elevated endogenous IFNs such as systemic sclerosis are strongly associated with PAH.

79 vels were elevated in serum of patients with systemic sclerosis associated PAH.

80 s that can be learnt from clinical trials of systemic sclerosis-associated ILD and idiopathic pulmona

81 Patients with systemic sclerosis-associated interstitial lung disease

82 Histologic assessment of patients with systemic sclerosis-associated PAH and the hypoxia/SU5416

83 uded vessels in patients with idiopathic and systemic sclerosis-associated PAH.

84 Systemic sclerosis-associated pulmonary artery hypertens

85 or autoimmune (polymyositis/dermatomyositis, systemic sclerosis, autoimmune hemolytic anemia, pernici

86 secreted by plasmacytoid dendritic cells in systemic sclerosis, both in circulation and in skin.

87 ransplantation (HSCT) benefits patients with systemic sclerosis but has been associated with signific

88 ve treatment option for patients with severe systemic sclerosis, but is associated with toxicity and

89 In the 2 patients with systemic sclerosis, D-OCT depicted megacapillaries, as w

90 by DNA microarray from 13 diffuse cutaneous systemic sclerosis (dSSc) patients enrolled in an open-l

91 miR-135b was measured in systemic sclerosis fibroblasts isolated from patients an

92 skin and pulmonary function in patients with systemic sclerosis for up to 2 years and is preferable t

93 date major histocompatibility complex-linked systemic sclerosis genetics, we performed genotyping of

94 Improved understanding of systemic sclerosis has allowed better management of the

95 ly a small proportion of the heritability of systemic sclerosis has been explained.

96 as a potential strategy for the treatment of systemic sclerosis has been gaining more widespread inte

97 opoietic stem-cell transplantation (HSCT) in systemic sclerosis have shown improvements in lung funct

98 specially juvenile dermatomyositis (JDM) and systemic sclerosis; however, little is known about the p

99 Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased t

100 patients with idiopathic pulmonary fibrosis, systemic sclerosis, hypertrophic cardiomyopathy, or myel

101 een concluded: the nonmyeloablative American Systemic Sclerosis Immune Suppression versus Transplant,

102 performed an exome-wide association study of systemic sclerosis in a Han Chinese population.

103 sults revealed three signals associated with systemic sclerosis in Han Chinese and suggested the impo

104 allele for systemic lupus erythematosus and systemic sclerosis in non-Hispanic white or Chinese subj

105 ransplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials.

106 The spectrum of renal complications in systemic sclerosis includes scleroderma renal crisis (SR

107 Systemic sclerosis is a complex disease with widespread

108 Systemic sclerosis is a rare disabling autoimmune diseas

109 Systemic sclerosis is a systemic autoimmune and connecti

110 Systemic sclerosis is an autoimmune connective tissue di

111 Systemic sclerosis is an autoimmune disease characterize

112 Systemic sclerosis is an autoimmune disease characterize

113 Systemic sclerosis is an orphan, systemic autoimmune dis

114 Systemic sclerosis is commonly complicated by pulmonary

115 of non-lethal complications associated with systemic sclerosis is substantial and is likely to becom

116 Although systemic sclerosis is uncommon, it has a high morbidity

117 n several inflammatory skin diseases, yet in systemic sclerosis, it can occur in all regions of the d

118 roblast in diverse fibrotic lesions, such as systemic sclerosis; kidney, liver, and lung fibrosis; an

119 , a common complication of limited cutaneous systemic sclerosis (lcSSc), is associated with alteratio

120 studies with rituximab in diffuse cutaneous systemic sclerosis lend support that B cells may be impo

121 Caveolin-1 was reduced in affected systemic sclerosis lungs and skin and in idiopathic pulm

122 derstanding of the disease in the context of systemic sclerosis may lead to novel diagnostic and ther

123 were aged younger than 60 years with diffuse systemic sclerosis, modified Rodnan skin scores (mRSS) o

124 Pulmonary arterial hypertension complicating systemic sclerosis occurs commonly and portends a poor p

125 We enrolled adults with progressive systemic sclerosis of 5 or fewer years' duration from fi

126 We assessed patients with diffuse systemic sclerosis or limited systemic sclerosis and int

127 ross all three cohorts, and in patients with systemic sclerosis or myelofibrosis in two of the three

128 kin fibroblasts from individuals with either systemic sclerosis or recessive dystrophic epidermolysis

129 idosis or collagen vascular diseases such as systemic sclerosis or rheumatoid arthritis; however, eac

130 Systemic sclerosis or scleroderma (SSc) is a complex aut

131 novo emergence of myofibroblasts such as in systemic sclerosis or scleroderma.

132 d coding and non-coding genes in relation to systemic sclerosis pathogenesis with a specific focus on

133 se and suggested the importance of LRP2BP in systemic sclerosis pathogenesis.

134 nd thereby improve the state of knowledge of systemic sclerosis pathogenesis.

135 I IFN-associated genes might be critical in systemic sclerosis pathogenesis.

136 assays of CD4(+) and CD8(+) T cells from 24 systemic sclerosis patients and 24 matched controls were

137 l randomized, controlled phase 2 trial in 19 systemic sclerosis patients and a large randomized phase

138 mer group, AKA were present in 4 of 20 (20%) systemic sclerosis patients and in 3 of 12 (25%) ankylos

139 Skin biopsy-derived RNAs from 14 early systemic sclerosis patients and six healthy individuals

140 oding RNAs are deregulated in skin tissue of systemic sclerosis patients suggesting a novel class of

141 ospective analyses of independent cohorts of systemic sclerosis patients treated with autologous stem

142 Stem cell transplantation of systemic sclerosis patients with lung involvement result

143 healthy human skin disappear in the skin of systemic sclerosis patients, and CD34(-), podoplanin(+),

144 is dysfunctional at the epigenetic level in systemic sclerosis patients, indicating that hypomethyla

145 ) were significantly elevated in the sera of systemic sclerosis patients.

146 In a cohort of systemic sclerosis patients/controls, SFVT analysis show

147 This activation phenotype of systemic sclerosis platelets may be secondary to autoimm

148 of systemic sclerosis and a leading cause of systemic sclerosis-related death.

149 In this study, we replicated key features of systemic sclerosis-related PAH in a mouse model.

150 atory deformation in study participants with systemic sclerosis-related pulmonary fibrosis compared w

151 with pulmonary hypertension (166 SScPAH, 49 systemic sclerosis-related pulmonary hypertension with i

152 We tested whether SScPAH or systemic sclerosis-related pulmonary hypertension with i

153 Cardiac involvement in systemic sclerosis (scleroderma [SSc]) adversely affects

154 The lung in systemic sclerosis (scleroderma) is susceptible to fibro

155 Systemic sclerosis (scleroderma, SSc) is a devastating f

156 Gastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common

157 nderstanding of fibrosis and vasculopathy in systemic sclerosis, scleroderma (SSc) largely mediated t

158 rials to assess changes in diffuse cutaneous systemic sclerosis skin disease over time.

159 c-Rel subunits within lesional psoriatic and systemic sclerosis skin revealed abnormal epidermal expr

160 Select examples include systemic sclerosis, spongiotic dermatitis, and cutaneous

161 te disease phenotypes in fibrillin-1 mutated systemic sclerosis (SS) and dextran-sulfate-sodium-induc

162 Systemic sclerosis (SSc or scleroderma) is an auto-immun

163 n extra-cutaneous organ system involved with systemic sclerosis (SSc) affecting approximately 90% of

164 Systemic sclerosis (SSc) affects both microvascular stru

165 number of genetic risk loci associated with systemic sclerosis (SSc) and Crohn's disease (CD), some

166 owth factor (CTGF; CCN2) is overexpressed in systemic sclerosis (SSc) and has been hypothesized to be

167 omenon occurs in virtually all patients with systemic sclerosis (SSc) and is often the earliest clini

168 data for elucidating the molecular basis of systemic sclerosis (SSc) and its various clinical manife

169 ltured dermal fibroblasts from patients with systemic sclerosis (SSc) and nephrogenic systemic fibros

170 the importance of interleukin-13 (IL-13) in systemic sclerosis (SSc) and other fibrotic diseases, it

171 dy is to investigate the association between systemic sclerosis (SSc) and periodontitis.

172 aberrant Wnt signaling has been linked with systemic sclerosis (SSc) and pulmonary fibrosis, we soug

173 ers (CTDs), including Marfan syndrome (MFS), systemic sclerosis (SSc) and Tight-skin (Tsk) mice.

174 e, incidence, survival, and risk factors for systemic sclerosis (SSc) and to compare these data to pr

175 tivation of the Smad1 pathway in fibrosis in systemic sclerosis (SSc) and to determine whether this p

176 increased in a large cohort of patients with systemic sclerosis (SSc) and whether OPN contributes to

177 Improved outcome measures in systemic sclerosis (SSc) are critical to finding active

178 for maintaining persistent organ fibrosis in systemic sclerosis (SSc) are not known but emerging evid

179 at Wnts might contribute to skin fibrosis in systemic sclerosis (SSc) by affecting the differentiatio

180 In this study, 1,833 systemic sclerosis (SSc) cases and 3,466 controls were g

181 The autoimmune disease systemic sclerosis (SSc) causes microvascular changes th

182 , observational study of a multiethnic early systemic sclerosis (SSc) cohort.

183 Heterogeneity in systemic sclerosis (SSc) confounds clinical trials.

184 blood cells (PBMCs) from some patients with systemic sclerosis (SSc) express an interferon-alpha (IF

185 and to determine the sensitivity of cultured systemic sclerosis (SSc) fibroblasts to Akt inhibition.

186 study was undertaken to examine responses of systemic sclerosis (SSc) fibroblasts to sphingosine 1-ph

187 been shown that inadequate vasculogenesis in systemic sclerosis (SSc) has been associated with an end

188 ells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified.

189 Systemic sclerosis (SSc) has the highest cause-specific

190 BACKGROUND & AIMS: Patients with systemic sclerosis (SSc) have impairments in gastrointes

191 Systemic sclerosis (SSc) is a chronic autoimmune disease

192 Systemic sclerosis (SSc) is a chronic idiopathic disease

193 Systemic sclerosis (SSc) is a clinically heterogeneous a

194 Systemic sclerosis (SSc) is a complex, multiorgan, autoi

195 Systemic sclerosis (SSc) is a connective tissue disorder

196 Systemic sclerosis (SSc) is a disease at the intersectio

197 Systemic sclerosis (SSc) is a disorder of systemic and d

198 Systemic sclerosis (SSc) is a generalized disorder of un

199 n present clinically, cardiac involvement in systemic sclerosis (SSc) is a major risk factor for deat

200 Systemic sclerosis (SSc) is a multi-organ fibrotic disea

201 Systemic sclerosis (SSc) is a multisystem inflammatory a

202 Systemic sclerosis (SSc) is a polygenic, autoimmune diso

203 Systemic sclerosis (SSc) is a rare autoimmune disorder c

204 Systemic sclerosis (SSc) is a rare systemic autoimmune d

205 Systemic sclerosis (SSc) is a spreading fibrotic disease

206 Skin fibrosis in systemic sclerosis (SSc) is accompanied by attrition of

207 Systemic sclerosis (SSc) is an autoimmune disease charac

208 Systemic sclerosis (SSc) is an autoimmune disease charac

209 Systemic sclerosis (SSc) is an autoimmune disease charac

210 Systemic sclerosis (SSc) is an autoimmune disease marked

211 Systemic sclerosis (SSc) is an autoimmune disease that s

212 Systemic sclerosis (SSc) is an autoimmune disorder chara

213 Systemic sclerosis (SSc) is an autoimmune disorder that

214 Systemic sclerosis (SSc) is associated with vasculopathy

215 Systemic sclerosis (SSc) is characterized by calcificati

216 Systemic sclerosis (SSc) is characterized by chronic inf

217 Systemic sclerosis (SSc) is characterized by microangiop

218 Systemic sclerosis (SSc) is manifested by fibrosis, vasc

219 Epidemiology studies suggest that systemic sclerosis (SSc) is more common, occurs at a you

220 Dermal fibroblasts were isolated from systemic sclerosis (SSc) patients and healthy control su

221 ulmonary vasculature of <2 mm in diameter in Systemic Sclerosis (SSc) patients with (n = 17) and with

222 ight stimulate both of these key features of systemic sclerosis (SSc) RECENT FINDINGS: Nucleic acid c

223 The role of tumor necrosis factor (TNF) in systemic sclerosis (SSc) remains controversial.

224 Systemic sclerosis (SSc) remains one of the last severe

225 amics and exercise capacity in patients with systemic sclerosis (SSc) spectrum-associated ePH treated

226 Systemic sclerosis (SSc), a collagen vascular disease ch

227 In systemic sclerosis (SSc), a common and aetiologically my

228 T lymphocytes play an important role in systemic sclerosis (SSc), a connective tissue disease ch

229 CD8(+)CD28(-) T cells in the pathogenesis of systemic sclerosis (SSc), a connective tissue disorder c

230 in the peripheral blood of individuals with systemic sclerosis (SSc), a disease characterized by fib

231 Systemic sclerosis (SSc), also known as scleroderma, is

232 ggested a role for pathogens as a trigger of systemic sclerosis (SSc), although neither a pathogen no

233 nchoalveolar lavage fluid from patients with systemic sclerosis (SSc), and in a CCL18 overexpression

234 need for effective antifibrotic therapies in systemic sclerosis (SSc), and in parallel a rapid develo

235 vement with dermal fibrosis is a hallmark of systemic sclerosis (SSc), and keratinocytes may be criti

236 ity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-beta-regu

237 isease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, popu

238 Fibrosis, the hallmark of systemic sclerosis (SSc), is characterized by persistent

239 Systemic sclerosis (SSc), or scleroderma, is a heterogen

240 n (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulm

241 ating tight skin (Tsk(-/+)) mice, a model of systemic sclerosis (SSc), with 4F decreases inflammation

242 uss recent advances in serologic testing for systemic sclerosis (SSc)-associated antibodies with resp

243 s now been shown to reduce the number of new systemic sclerosis (SSc)-related digital ulcers in two m

244 th factor (PDGF) may play a critical role in systemic sclerosis (SSc)-related interstitial lung disea

245 ophosphamide pulse, a standard treatment for systemic sclerosis (SSc)-related interstitial lung disea

246 Systemic sclerosis (SSc)-related pulmonary fibrosis, for

247 FNs are implicated in the pathophysiology of systemic sclerosis (SSc).

248 o be observed in fibrotic disorders, such as systemic sclerosis (SSc).

249 critical early event in the pathogenesis of systemic sclerosis (SSc).

250 have been implicated in the pathogenesis of systemic sclerosis (SSc).

251 ung disease is the leading cause of death in systemic sclerosis (SSc).

252 istration of chest CT scans in patients with systemic sclerosis (SSc).

253 or contributor to morbidity and mortality in systemic sclerosis (SSc).

254 Wnt/beta-catenin signaling in the context of systemic sclerosis (SSc).

255 proteins underlies the fibrotic phenotype of systemic sclerosis (SSc).

256 leading cause of mortality in patients with systemic sclerosis (SSc).

257 an important cause of death in patients with systemic sclerosis (SSc).

258 ulmonary fibrosis in study participants with systemic sclerosis (SSc).

259 ly has a crucial role in the pathogenesis of systemic sclerosis (SSc).

260 the leading causes of death in patients with systemic sclerosis (SSc).

261 is implicated as a participatory pathway in systemic sclerosis (SSc).

262 gene expression in the skin of patients with systemic sclerosis (SSc).

263 ersing of the fibrotic process is limited in systemic sclerosis (SSc).

264 st activation in fibrotic diseases including systemic sclerosis (SSc).

265 data and interstitial lung disease (ILD) - a systemic sclerosis (SSc, or scleroderma) clinical phenot

266 exist in the susceptibility and severity of systemic sclerosis (SSc, scleroderma) and are responsibl

267 ry fibrosis is an important manifestation in systemic sclerosis (SSc, scleroderma) where it portends

268 PAH associated with systemic sclerosis (SSc-PAH) has a substantially worse p

269 arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH).

270 and its receptor, PDGFR, promote fibrosis in systemic sclerosis (SSc; scleroderma) dermal fibroblasts

271 The underlying pathogenesis of systemic sclerosis (SSc; scleroderma) involves a complex

272 Systemic sclerosis (SSc; scleroderma) is characterized b

273 leading cause of morbidity and mortality in systemic sclerosis (SSc; scleroderma), and interstitial

274 enda for research on psychosocial aspects of systemic sclerosis (SSc; scleroderma).

275 fibrosis, the most characteristic feature of systemic sclerosis (SSc; scleroderma).

276 Scleroderma (systemic sclerosis [SSc]) is a complex connective tissue

277 Scleroderma (systemic sclerosis [SSc]), is characterized by progressi

278 ducing functional disability in scleroderma (systemic sclerosis; SSc).

279 S scores comparable with scores reported for systemic sclerosis, systemic lupus erythematosus, and mu

280 y of proteins not previously associated with systemic sclerosis that provide insight into pathogenesi

281 Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC wa

282 sorders, such as scleroderma and progressive systemic sclerosis, the direct consequences of IL-33 rel

283 In systemic sclerosis, these repair processes appear to run

284 In systemic sclerosis, this compartment expands, but lympho

285 have been implicated in the pathogenesis of systemic sclerosis through mechanisms beyond the previou

286 lines for cardiac screening of patients with systemic sclerosis to assess treatment-related risk from

287 that have a well-documented association with systemic sclerosis to determine whether these SNPs are a

288 ess in understanding genetic associations of systemic sclerosis to explain the observed heritability.

289 ion data from skin biopsies of patients with systemic sclerosis treated with five therapies: mycophen

290 oid arthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis or idiopathic inflammator

291 mean (+/-SD) level of CXCL4 in patients with systemic sclerosis was 25,624+/-2652 pg per milliliter,

292 ed and unequivocally effective currently for systemic sclerosis, we have come a long way in the past

293 six healthy volunteers and six patients with systemic sclerosis were imaged at 1.5-T nonenhanced FSD

294 9, 156 patients with early diffuse cutaneous systemic sclerosis were recruited and followed up until

295 -three patients with early diffuse cutaneous systemic sclerosis were studied at 11 international cent

296 thritis [RA], 12 psoriatic arthritis, and 12 systemic sclerosis) were recruited together with 12 heal

297 o cohorts of patients with diffuse cutaneous systemic sclerosis, were identified as differentially re

298 appear to operate in Sjogren's syndrome and systemic sclerosis whereas only the IRF5-TNPO3 gene-span

299 from healthy persons and from patients with systemic sclerosis who had distinct clinical phenotypes.

300 Patients who had systemic sclerosis with an onset of the first non-Raynau